0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multiple Myeloma Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Published Date: December 2022
|
Report Code: QYRE-Auto-9L384
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Multiple Myeloma Therapeutics Market Insights Forecast to 2028
BUY CHAPTERS

Global Multiple Myeloma Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Code: QYRE-Auto-9L384
Report
December 2022
Pages:106
QYResearch
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Multiple Myeloma Therapeutics estimated at US$ 30460 million in the year 2022, is projected to reach a revised size of US$ 55870 million by 2028, growing at a CAGR of 10.6% during the forecast period 2022-2028.

The USA market for Multiple Myeloma Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Multiple Myeloma Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Multiple Myeloma Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key companies of Multiple Myeloma Therapeutics include Janssen Biotech, Inc., Bristol-Myers Squibb, Novartis AG, Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Celgene Corporation, Kesios Therapeutics Limited, Amgene, Inc. and Genzyme Corporation, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Multiple Myeloma Therapeutics companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Multiple Myeloma Therapeutics market. Further, it explains the major drivers and regional dynamics of the global Multiple Myeloma Therapeutics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Multiple Myeloma Therapeutics Segment by Type

Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments

Multiple Myeloma Therapeutics Segment by Application

Hospitals
Clinics
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Multiple Myeloma Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Multiple Myeloma Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Multiple Myeloma Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Multiple Myeloma Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multiple Myeloma Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Multiple Myeloma Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Multiple Myeloma Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Janssen Biotech, Inc., Bristol-Myers Squibb, Novartis AG, Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Celgene Corporation, Kesios Therapeutics Limited, Amgene, Inc. and Genzyme Corporation, etc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Myeloma Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Radiation
1.2.4 Stem Cell Transplant
1.2.5 Other Supportive Treatments
1.3 Market by Application
1.3.1 Global Multiple Myeloma Therapeutics Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Multiple Myeloma Therapeutics Market Size (2017-2028)
2.2 Multiple Myeloma Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Multiple Myeloma Therapeutics Market Size by Region (2017-2022)
2.4 Global Multiple Myeloma Therapeutics Market Size Forecast by Region (2023-2028)
2.5 Global Top Multiple Myeloma Therapeutics Countries Ranking by Market Size
3 Multiple Myeloma Therapeutics Competitive by Company
3.1 Global Multiple Myeloma Therapeutics Revenue by Players
3.1.1 Global Multiple Myeloma Therapeutics Revenue by Players (2017-2022)
3.1.2 Global Multiple Myeloma Therapeutics Market Share by Players (2017-2022)
3.2 Global Multiple Myeloma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Multiple Myeloma Therapeutics Revenue
3.4 Global Multiple Myeloma Therapeutics Market Concentration Ratio
3.4.1 Global Multiple Myeloma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Myeloma Therapeutics Revenue in 2021
3.5 Global Multiple Myeloma Therapeutics Key Players Head office and Area Served
3.6 Key Players Multiple Myeloma Therapeutics Product Solution and Service
3.7 Date of Enter into Multiple Myeloma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Multiple Myeloma Therapeutics Breakdown Data by Type
4.1 Global Multiple Myeloma Therapeutics Historic Revenue by Type (2017-2022)
4.2 Global Multiple Myeloma Therapeutics Forecasted Revenue by Type (2023-2028)
5 Global Multiple Myeloma Therapeutics Breakdown Data by Application
5.1 Global Multiple Myeloma Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Multiple Myeloma Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Multiple Myeloma Therapeutics Revenue by Company (2020-2022)
6.2 North America Multiple Myeloma Therapeutics Revenue by Type (2017-2028)
6.3 North America Multiple Myeloma Therapeutics Revenue by Application (2017-2028)
6.4 North America Multiple Myeloma Therapeutics Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Multiple Myeloma Therapeutics Revenue by Company (2020-2022)
7.2 Europe Multiple Myeloma Therapeutics Revenue by Type (2017-2028)
7.3 Europe Multiple Myeloma Therapeutics Revenue by Application (2017-2028)
7.4 Europe Multiple Myeloma Therapeutics Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Multiple Myeloma Therapeutics Revenue by Company (2020-2022)
8.2 Asia Pacific Multiple Myeloma Therapeutics Revenue by Type (2017-2028)
8.3 Asia Pacific Multiple Myeloma Therapeutics Revenue by Application (2017-2028)
8.4 Asia Pacific Multiple Myeloma Therapeutics Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Multiple Myeloma Therapeutics Revenue by Company (2020-2022)
9.2 Latin America Multiple Myeloma Therapeutics Revenue by Type (2017-2028)
9.3 Latin America Multiple Myeloma Therapeutics Revenue by Application (2017-2028)
9.4 Latin America Multiple Myeloma Therapeutics Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Multiple Myeloma Therapeutics Revenue by Company (2020-2022)
10.2 Middle East and Africa Multiple Myeloma Therapeutics Revenue by Type (2017-2028)
10.3 Middle East and Africa Multiple Myeloma Therapeutics Revenue by Application (2017-2028)
10.4 Middle East and Africa Multiple Myeloma Therapeutics Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Company Details
11.1.2 Janssen Biotech, Inc. Business Overview
11.1.3 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Products and Services
11.1.4 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.1.5 Janssen Biotech, Inc. Multiple Myeloma Therapeutics SWOT Analysis
11.1.6 Janssen Biotech, Inc. Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Multiple Myeloma Therapeutics Products and Services
11.2.4 Bristol-Myers Squibb Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.2.5 Bristol-Myers Squibb Multiple Myeloma Therapeutics SWOT Analysis
11.2.6 Bristol-Myers Squibb Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Multiple Myeloma Therapeutics Products and Services
11.3.4 Novartis AG Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.3.5 Novartis AG Multiple Myeloma Therapeutics SWOT Analysis
11.3.6 Novartis AG Recent Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Products and Services
11.4.4 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.4.5 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics SWOT Analysis
11.4.6 Bristol-Myers Squibb Company Recent Developments
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Details
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Products and Services
11.5.4 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.5.5 Millennium Pharmaceuticals Multiple Myeloma Therapeutics SWOT Analysis
11.5.6 Millennium Pharmaceuticals Recent Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Details
11.6.2 Celgene Corporation Business Overview
11.6.3 Celgene Corporation Multiple Myeloma Therapeutics Products and Services
11.6.4 Celgene Corporation Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.6.5 Celgene Corporation Multiple Myeloma Therapeutics SWOT Analysis
11.6.6 Celgene Corporation Recent Developments
11.7 Kesios Therapeutics Limited
11.7.1 Kesios Therapeutics Limited Company Details
11.7.2 Kesios Therapeutics Limited Business Overview
11.7.3 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Products and Services
11.7.4 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.7.5 Kesios Therapeutics Limited Multiple Myeloma Therapeutics SWOT Analysis
11.7.6 Kesios Therapeutics Limited Recent Developments
11.8 Amgene, Inc.
11.8.1 Amgene, Inc. Company Details
11.8.2 Amgene, Inc. Business Overview
11.8.3 Amgene, Inc. Multiple Myeloma Therapeutics Products and Services
11.8.4 Amgene, Inc. Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.8.5 Amgene, Inc. Multiple Myeloma Therapeutics SWOT Analysis
11.8.6 Amgene, Inc. Recent Developments
11.9 Genzyme Corporation
11.9.1 Genzyme Corporation Company Details
11.9.2 Genzyme Corporation Business Overview
11.9.3 Genzyme Corporation Multiple Myeloma Therapeutics Products and Services
11.9.4 Genzyme Corporation Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.9.5 Genzyme Corporation Multiple Myeloma Therapeutics SWOT Analysis
11.9.6 Genzyme Corporation Recent Developments
11.10 Juno Therapeutics
11.10.1 Juno Therapeutics Company Details
11.10.2 Juno Therapeutics Business Overview
11.10.3 Juno Therapeutics Multiple Myeloma Therapeutics Products and Services
11.10.4 Juno Therapeutics Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022)
11.10.5 Juno Therapeutics Multiple Myeloma Therapeutics SWOT Analysis
11.10.6 Juno Therapeutics Recent Developments
12 Multiple Myeloma Therapeutics Market Dynamics
12.1 Multiple Myeloma Therapeutics Market Trends
12.2 Multiple Myeloma Therapeutics Market Drivers
12.3 Multiple Myeloma Therapeutics Market Challenges
12.4 Multiple Myeloma Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
    Table 1. Global Multiple Myeloma Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Radiation
    Table 4. Key Players of Stem Cell Transplant
    Table 5. Key Players of Other Supportive Treatments
    Table 6. Global Multiple Myeloma Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Multiple Myeloma Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
    Table 8. Global Multiple Myeloma Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 9. Global Multiple Myeloma Therapeutics Revenue Market Share by Region (2017-2022)
    Table 10. Global Multiple Myeloma Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 11. Global Multiple Myeloma Therapeutics Market Share by Players (2017-2022)
    Table 12. Global Top Multiple Myeloma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Therapeutics as of 2021)
    Table 13. Ranking of Global Top Multiple Myeloma Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 14. Global 5 Largest Players Market Share by Multiple Myeloma Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 15. Key Players Headquarters and Area Served
    Table 16. Key Players Multiple Myeloma Therapeutics Product Solution and Service
    Table 17. Date of Key Manufacturers Enter into Multiple Myeloma Therapeutics Market
    Table 18. Mergers & Acquisitions, Expansion Plans
    Table 19. Global Multiple Myeloma Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 20. Global Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2022)
    Table 21. Global Multiple Myeloma Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 22. Global Multiple Myeloma Therapeutics Revenue Market Share by Type (2023-2028)
    Table 23. Global Multiple Myeloma Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 24. Global Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2022)
    Table 25. Global Multiple Myeloma Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 26. Global Multiple Myeloma Therapeutics Revenue Market Share by Application (2023-2028)
    Table 27. North America Multiple Myeloma Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 28. North America Multiple Myeloma Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 29. North America Multiple Myeloma Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 30. North America Multiple Myeloma Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 31. North America Multiple Myeloma Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 32. North America Multiple Myeloma Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 33. North America Multiple Myeloma Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 34. Europe Multiple Myeloma Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 35. Europe Multiple Myeloma Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 36. Europe Multiple Myeloma Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 37. Europe Multiple Myeloma Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 38. Europe Multiple Myeloma Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 39. Europe Multiple Myeloma Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 40. Europe Multiple Myeloma Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 41. Asia Pacific Multiple Myeloma Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 42. Asia Pacific Multiple Myeloma Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 43. Asia Pacific Multiple Myeloma Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Multiple Myeloma Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Multiple Myeloma Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Multiple Myeloma Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Multiple Myeloma Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 48. Latin America Multiple Myeloma Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 49. Latin America Multiple Myeloma Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 50. Latin America Multiple Myeloma Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 51. Latin America Multiple Myeloma Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 52. Latin America Multiple Myeloma Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 53. Latin America Multiple Myeloma Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 54. Latin America Multiple Myeloma Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 55. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 56. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Multiple Myeloma Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 62. Janssen Biotech, Inc. Company Details
    Table 63. Janssen Biotech, Inc. Business Overview
    Table 64. Janssen Biotech, Inc. Multiple Myeloma Therapeutics Product and Services
    Table 65. Janssen Biotech, Inc. Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 66. Janssen Biotech, Inc. Multiple Myeloma Therapeutics SWOT Analysis
    Table 67. Janssen Biotech, Inc. Recent Developments
    Table 68. Bristol-Myers Squibb Company Details
    Table 69. Bristol-Myers Squibb Business Overview
    Table 70. Bristol-Myers Squibb Multiple Myeloma Therapeutics Product and Services
    Table 71. Bristol-Myers Squibb Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 72. Bristol-Myers Squibb Multiple Myeloma Therapeutics SWOT Analysis
    Table 73. Bristol-Myers Squibb Recent Developments
    Table 74. Novartis AG Company Details
    Table 75. Novartis AG Business Overview
    Table 76. Novartis AG Multiple Myeloma Therapeutics Product and Services
    Table 77. Novartis AG Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 78. Novartis AG Multiple Myeloma Therapeutics SWOT Analysis
    Table 79. Novartis AG Recent Developments
    Table 80. Bristol-Myers Squibb Company Company Details
    Table 81. Bristol-Myers Squibb Company Business Overview
    Table 82. Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Product and Services
    Table 83. Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 84. Bristol-Myers Squibb Company Multiple Myeloma Therapeutics SWOT Analysis
    Table 85. Bristol-Myers Squibb Company Recent Developments
    Table 86. Millennium Pharmaceuticals Company Details
    Table 87. Millennium Pharmaceuticals Business Overview
    Table 88. Millennium Pharmaceuticals Multiple Myeloma Therapeutics Product and Services
    Table 89. Millennium Pharmaceuticals Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 90. Millennium Pharmaceuticals Multiple Myeloma Therapeutics SWOT Analysis
    Table 91. Millennium Pharmaceuticals Recent Developments
    Table 92. Celgene Corporation Company Details
    Table 93. Celgene Corporation Business Overview
    Table 94. Celgene Corporation Multiple Myeloma Therapeutics Product and Services
    Table 95. Celgene Corporation Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 96. Celgene Corporation Multiple Myeloma Therapeutics SWOT Analysis
    Table 97. Celgene Corporation Recent Developments
    Table 98. Kesios Therapeutics Limited Company Details
    Table 99. Kesios Therapeutics Limited Business Overview
    Table 100. Kesios Therapeutics Limited Multiple Myeloma Therapeutics Product and Services
    Table 101. Kesios Therapeutics Limited Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 102. Kesios Therapeutics Limited Multiple Myeloma Therapeutics SWOT Analysis
    Table 103. Kesios Therapeutics Limited Recent Developments
    Table 104. Amgene, Inc. Company Details
    Table 105. Amgene, Inc. Business Overview
    Table 106. Amgene, Inc. Multiple Myeloma Therapeutics Product and Services
    Table 107. Amgene, Inc. Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 108. Amgene, Inc. Multiple Myeloma Therapeutics SWOT Analysis
    Table 109. Amgene, Inc. Recent Developments
    Table 110. Genzyme Corporation Company Details
    Table 111. Genzyme Corporation Business Overview
    Table 112. Genzyme Corporation Multiple Myeloma Therapeutics Product and Services
    Table 113. Genzyme Corporation Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 114. Genzyme Corporation Multiple Myeloma Therapeutics SWOT Analysis
    Table 115. Genzyme Corporation Recent Developments
    Table 116. Juno Therapeutics Company Details
    Table 117. Juno Therapeutics Business Overview
    Table 118. Juno Therapeutics Multiple Myeloma Therapeutics Product and Services
    Table 119. Juno Therapeutics Multiple Myeloma Therapeutics Revenue in Multiple Myeloma Therapeutics Business (2017-2022) & (US$ Million)
    Table 120. Juno Therapeutics Multiple Myeloma Therapeutics SWOT Analysis
    Table 121. Juno Therapeutics Recent Developments
    Table 122. Multiple Myeloma Therapeutics Market Trends
    Table 123. Multiple Myeloma Therapeutics Market Drivers
    Table 124. Multiple Myeloma Therapeutics Market Challenges
    Table 125. Multiple Myeloma Therapeutics Market Restraints
    Table 126. Research Programs/Design for This Report
    Table 127. Key Data Information from Secondary Sources
    Table 128. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Multiple Myeloma Therapeutics Sales Market Share by Type: 2021 VS 2028
    Figure 2. Chemotherapy Features
    Figure 3. Radiation Features
    Figure 4. Stem Cell Transplant Features
    Figure 5. Other Supportive Treatments Features
    Figure 6. Global Multiple Myeloma Therapeutics Sales Market Share by Application: 2021 VS 2028
    Figure 7. Hospitals Case Studies
    Figure 8. Clinics Case Studies
    Figure 9. Others Case Studies
    Figure 10. Multiple Myeloma Therapeutics Report Years Considered
    Figure 11. Global Multiple Myeloma Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Multiple Myeloma Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 13. Global Multiple Myeloma Therapeutics Market Size Market Share by Region: 2021 VS 2028
    Figure 14. Global Multiple Myeloma Therapeutics Revenue Market Share by Region in 2017 VS 2022
    Figure 15. Global Top 10 Multiple Myeloma Therapeutics Countries Ranking by Market Size (US$ Million) in 2021
    Figure 16. Global Multiple Myeloma Therapeutics Market Share by Players in 2021
    Figure 17. Global Top Multiple Myeloma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Therapeutics as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Multiple Myeloma Therapeutics Revenue in 2021
    Figure 19. North America Multiple Myeloma Therapeutics Revenue Market Share by Company in 2021
    Figure 20. North America Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 21. North America Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 22. North America Multiple Myeloma Therapeutics Revenue Share by Country (2017-2028)
    Figure 23. U.S. Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 24. Canada Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 25. Europe Multiple Myeloma Therapeutics Revenue Market Share by Company in 2021
    Figure 26. Europe Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 27. Europe Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 28. Europe Multiple Myeloma Therapeutics Revenue Share by Country (2017-2028)
    Figure 29. Germany Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 30. France Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 31. U.K. Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 32. Italy Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 33. Russia Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Multiple Myeloma Therapeutics Revenue Market Share by Company in 2021
    Figure 35. Asia Pacific Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Multiple Myeloma Therapeutics Revenue Share by Region (2017-2028)
    Figure 38. China Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 39. Japan Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 40. South Korea Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 41. India Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 42. Australia Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 43. Taiwan Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 44. Indonesia Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 45. Thailand Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 46. Malaysia Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 47. Philippines Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 48. Vietnam Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 49. Latin America Multiple Myeloma Therapeutics Revenue Market Share by Company in 2021
    Figure 50. Latin America Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 51. Latin America Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 52. Latin America Multiple Myeloma Therapeutics Revenue Share by Country (2017-2028)
    Figure 53. Mexico Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 54. Brazil Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 55. Argentina Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 56. Middle East and Africa Multiple Myeloma Therapeutics Revenue Market Share by Company in 2021
    Figure 57. Middle East and Africa Multiple Myeloma Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 58. Middle East and Africa Multiple Myeloma Therapeutics Revenue Market Share by Application (2017-2028)
    Figure 59. Middle East and Africa Multiple Myeloma Therapeutics Revenue Share by Country (2017-2028)
    Figure 60. Turkey Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 61. Saudi Arabia Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 62. U.A.E Multiple Myeloma Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 63. Janssen Biotech, Inc. Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 65. Novartis AG Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 66. Bristol-Myers Squibb Company Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 67. Millennium Pharmaceuticals Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 68. Celgene Corporation Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 69. Kesios Therapeutics Limited Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 70. Amgene, Inc. Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 71. Genzyme Corporation Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 72. Juno Therapeutics Revenue Growth Rate in Multiple Myeloma Therapeutics Business (2017-2022)
    Figure 73. Bottom-up and Top-down Approaches for This Report
    Figure 74. Data Triangulation
    Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5600

This license allows only one user to access the PDF.
Electronic (PDF)

$8400

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11200

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS